Cosmos Health Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cosmos Health Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.27M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $54.43M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $53.38M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $50.35M | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $56.24M | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $55.41M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | $39.68M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $37.08M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $30.01M | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | $6.76M | Apr 17, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.90M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.31M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $4.35M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $5.96M | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $8.33M | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $8.06M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | $3.66M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $2.41M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.96M | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | $601.0K | Apr 17, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.14M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($16.18M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($18.54M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($13.83M) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | ($7.96M) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $820.8K | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | ($3.30M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($9.06M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($6.21M) | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | ($601.0K) | Apr 17, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.70M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($15.54M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($21.83M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($7.47M) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | ($4.53M) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $2.71M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | ($255.8K) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($1.23M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($4.87M) | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | ($202.5K) | Apr 17, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $519.4K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $533.3K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $164.9K | Apr 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.45M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($7.72M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($15.64M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($14.87M) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | ($7.10M) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | ($11.50M) | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | ($4.79M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($1.56M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($8.76M) | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | ($2.13M) | Apr 17, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $418.1K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $74.2K | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $581.4K | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $117.7K | Dec 16, 2022 |
| FY2018 | Dec 31, 2018 | $503.4K | Apr 18, 2019 |
| FY2018 | Dec 31, 2017 | $55.3K | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | $12.8K | Apr 17, 2018 |
| FY2015 | Dec 31, 2015 | $44.0K | Apr 20, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.48M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $54.31M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $66.01M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $68.04M | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $49.43M | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $43.84M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | $23.88M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $20.69M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.68M | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | $3.12M | Apr 17, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.05M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $29.78M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $29.97M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $28.38M | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $45.05M | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $48.01M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | $30.34M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $24.01M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $13.70M | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | $4.87M | Apr 17, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.42M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $24.53M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $36.04M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $39.28M | Apr 15, 2025 |
| FY2023 | Dec 31, 2021 | $4.38M | Aug 5, 2024 |
| FY2022 | Dec 31, 2020 | ($4.16M) | Apr 12, 2023 |
| FY2021 | Jan 1, 2020 | ($6.46M) | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | ($6.46M) | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | ($3.32M) | Apr 15, 2021 |
| FY2019 | Jan 1, 2018 | ($3.03M) | Apr 14, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $49.7K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $49.7K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $49.7K | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | $49.7K | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $49.7K | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | $49.7K | Apr 15, 2021 |
| FY2018 | Dec 31, 2018 | ($14.5K) | Apr 18, 2019 |
| FY2025 | Dec 19, 2018 | $49.7K | Apr 15, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($133.17M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($114.02M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($91.64M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($66.23M) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | ($34.35M) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | ($18.75M) | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | ($19.57M) | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | ($16.27M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($7.21M) | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | ($1.00M) | Apr 17, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $715.7K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $315.1K | Apr 15, 2026 |
| FY2022 | Dec 31, 2022 | $20.75M | Apr 12, 2023 |
| FY2022 | Dec 31, 2021 | $286.5K | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | $628.4K | Dec 16, 2022 |
| FY2021 | Dec 31, 2019 | $38.5K | Dec 16, 2022 |
| FY2020 | Dec 31, 2018 | $864.3K | Apr 15, 2021 |
| FY2018 | Dec 31, 2017 | $782.9K | Apr 18, 2019 |
| FY2018 | Dec 31, 2016 | $716.6K | Apr 18, 2019 |
| FY2017 | Dec 31, 2015 | $198.0K | Apr 17, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78M | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | $4.11M | Apr 15, 2025 |
| FY2023 | Dec 31, 2023 | $4.61M | Aug 5, 2024 |
| FY2022 | Dec 31, 2022 | $5.02M | Apr 12, 2023 |
| FY2021 | Dec 31, 2021 | $17.91M | Dec 16, 2022 |
| FY2020 | Dec 31, 2020 | $10.77M | Apr 15, 2021 |
| FY2020 | Dec 31, 2019 | $0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | $145.5K | Apr 14, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (33) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | (23) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 18, 2019 |
| FY2016 | Dec 31, 2016 | 0 | Apr 17, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (33) | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | (23) | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | 80,741 | Apr 17, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.07M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 23.60M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 15.90M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 10.59M | Aug 5, 2024 |
| FY2022 | Dec 31, 2021 | 686,283 | Apr 12, 2023 |
| FY2021 | Dec 31, 2020 | 13.07M | Dec 16, 2022 |
| FY2020 | Dec 31, 2019 | 12.86M | Apr 15, 2021 |
| FY2019 | Dec 31, 2018 | 13.69M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 12.67M | Apr 18, 2019 |
| FY2017 | Dec 31, 2016 | 12.59M | Apr 17, 2018 |